Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)

Hypophosphatasia Clinical Trial

Official title:

Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) Observational Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04925804
• Other study ID #: HPP genetics-2020
• Status: Completed
• Start date: June 2, 2021
• Est. completion date: December 2, 2021

Study information

• Verified date: December 2021
• Source: CENTOGENE GmbH Rostock
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Observational study to perform Whole Genome Sequencing in participants clinically suspected for HPP and negative for known pathogenic ALPL variants

Description:

Hypophosphatasia (HPP) is a rare Inborn Error of Metabolism (IEM), characterized by low tissue-nonspecific isoenzyme of alkaline phosphatase (ALP) activity. Alkaline phosphatase (ALP) is crucial for osteoid mineralization. Its main substrate in bone is pyrophosphate (PPi), a natural inhibitor of mineralization. ALP cleaves pyrophosphate into its two phosphate moieties, which then become available to the mineralization process. This ALP deficiency results in accumulation of its substrates, mainly inorganic pyrophosphate (PPi), pyridoxal-5-phosphate (PLP), and phosphoethanolamine (PEA). Beyond the bone and the Central Nervous System (CNS), ALP deficiency has an impact on a number of other organs and systems, resulting in a broad range of manifestations, including dental (premature tooth loss), muscular (muscle weakness, delayed walking, abnormal gait), rheumatic (calcium pyrophosphate deposition disease, fibromyalgia, fatigue, joint laxity), eye (calcifications), renal (nephrocalcinosis, kidney stones, renal failure), and gastrointestinal tract disturbance (gastroesophageal reflux). The specific symptoms can vary greatly from one person to another, sometimes even among members of the same family. There are five major clinical forms of HPP (perinatal, infantile, childhood, adult, and odontohypophosphatasia), ranging from an extremely severe form that can cause stillbirth to a form associated with only premature loss of baby (deciduous) teeth, but no bone abnormalities. The genetic reason of Hypophosphatasia is mainly caused by mutations in the ALPL gene, coding for the tissue nonspecific alkaline phosphatase isoenzyme. At least 397 distinct pathogenic variants (predominantly missense variants) were described to lead to low levels of the ALP enzyme. HPP can be inherited in an autosomal recessive (most perinatal and infantile forms) or autosomal dominant manner (typically the adult form and odontohypophosphatasia). Since ALPL dependent prevalence is very low, while symptoms overlapping HPP are much more common, other primary - genetic - forms of HPP-like symptoms are to be sought and characterized. The HPP genetics study aims to characterize the genetic background of HPP participants, who do not have pathogenic variant/s in the ALPL gene.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: December 2, 2021
• Est. primary completion date: December 2, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

• Informed consent is obtained from the participant or from the parent / legal guardian
• The participant is clinically suspected for HPP
• The participant does not have pathogenic variant/s in the ALPL gene
• The participant showed low alkaline phosphatase levels (age- and sex-adjusted) on at least two occasions at least a month apart based on the local laboratory reference range
• None of these conditions are present:
• Celiac disease and
• Clofibrate therapy and
• Cleidocranial dysplasia and
• Cushing's syndrome and
• Hypothyroidism and
• Massive Blood transfusion and
• Milk-alkali syndrome and
• Multiple myeloma and
• Osteogenesis imperfecta, type II and
• Pernicious or profound anemia and
• Starvation and
• Vitamin C deficiency and
• Vitamin D intoxication and
• Zinc deficiency and
• Magnesium deficiency

Related Conditions & MeSH terms

• Hypophosphatasia

Locations

Country	Name	City	State
Germany	Universität Würzburg - Klinische Studieneinheit, Orthopädische Klinik	Würzburg

Sponsors (2)

Lead Sponsor	Collaborator
CENTOGENE GmbH Rostock	Alexion Pharmaceuticals

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Genetic analysis (WGS) of participants clinically suspected for HPP	Analyis of Whole Genome Sequencing data in participants clinically suspected for HPP disease to characterize the genetic background of these 16 HPP subjects, who do not have pathogenic variant/s in the ALPL gene.	6 months
Secondary	Analysis and identification of genetic variants	Identification and validation of genetic variants in the selected cohort (16 WGS subjects; see Outcome 1) since ALPL dependent prevalence is very low, while symptoms overlapping HPP are much more common, other primary - genetic - forms of HPP-like symptoms are to be sought and characterized.	6 months